306 related articles for article (PubMed ID: 21922136)
1. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
Nobuoka D; Motomura Y; Shirakawa H; Yoshikawa T; Kuronuma T; Takahashi M; Nakachi K; Ishii H; Furuse J; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kinoshita T; Komori H; Baba H; Fujiwara T; Nakatsura T
Int J Oncol; 2012 Jan; 40(1):63-70. PubMed ID: 21922136
[TBL] [Abstract][Full Text] [Related]
2. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
3. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
Yoshikawa T; Nakatsugawa M; Suzuki S; Shirakawa H; Nobuoka D; Sakemura N; Motomura Y; Tanaka Y; Hayashi S; Nakatsura T
Cancer Sci; 2011 May; 102(5):918-25. PubMed ID: 21281401
[TBL] [Abstract][Full Text] [Related]
4. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
Sawada Y; Yoshikawa T; Nobuoka D; Shirakawa H; Kuronuma T; Motomura Y; Mizuno S; Ishii H; Nakachi K; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Takayama T; Yamao K; Uesaka K; Furuse J; Kinoshita T; Nakatsura T
Clin Cancer Res; 2012 Jul; 18(13):3686-96. PubMed ID: 22577059
[TBL] [Abstract][Full Text] [Related]
6. [Possibilities of glypican-3-specific immunotherapy for hepatocellular carcinoma].
Komori H; Nakatsura T; Beppu T; Nishimura Y; Baba H
Gan To Kagaku Ryoho; 2006 Nov; 33(12):1742-4. PubMed ID: 17212093
[TBL] [Abstract][Full Text] [Related]
7. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses.
Zerbini A; Pilli M; Penna A; Pelosi G; Schianchi C; Molinari A; Schivazappa S; Zibera C; Fagnoni FF; Ferrari C; Missale G
Cancer Res; 2006 Jan; 66(2):1139-46. PubMed ID: 16424051
[TBL] [Abstract][Full Text] [Related]
8. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.
Suzuki S; Yoshikawa T; Hirosawa T; Shibata K; Kikkawa F; Akatsuka Y; Nakatsura T
Cancer Sci; 2011 Sep; 102(9):1622-9. PubMed ID: 21668581
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.
Mizukoshi E; Yamashita T; Arai K; Sunagozaka H; Ueda T; Arihara F; Kagaya T; Yamashita T; Fushimi K; Kaneko S
Hepatology; 2013 Apr; 57(4):1448-57. PubMed ID: 23174905
[TBL] [Abstract][Full Text] [Related]
11. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
12. Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis.
Hayashi E; Motomura Y; Shirakawa H; Yoshikawa T; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
Oncol Rep; 2009 Jul; 22(1):149-54. PubMed ID: 19513517
[TBL] [Abstract][Full Text] [Related]
13. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
Sawada Y; Nakatsura T
Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
[TBL] [Abstract][Full Text] [Related]
14. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
Nakatsura T; Komori H; Kubo T; Yoshitake Y; Senju S; Katagiri T; Furukawa Y; Ogawa M; Nakamura Y; Nishimura Y
Clin Cancer Res; 2004 Dec; 10(24):8630-40. PubMed ID: 15623647
[TBL] [Abstract][Full Text] [Related]
15. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
Nishimura Y; Nakatsura T; Senju S
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):383-91. PubMed ID: 18974622
[TBL] [Abstract][Full Text] [Related]
16. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection.
Kagawa T; Koizumi J; Kojima S; Nagata N; Numata M; Watanabe N; Watanabe T; Mine T;
Cancer; 2010 Aug; 116(15):3638-44. PubMed ID: 20564097
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of safety and efficacy for transcatheter arterial chemoembolization alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and their prognosis factors].
Zhao M; Wang JP; Li W; Huang ZL; Zhang FJ; Fan WJ; Zhang L; Li XS; Pan CC; Wu PH
Zhonghua Yi Xue Za Zhi; 2011 May; 91(17):1167-72. PubMed ID: 21756768
[TBL] [Abstract][Full Text] [Related]
18. [Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation].
Wang YB; Chen MH; Yan K; Yang W; Dai Y; Yin SS
Ai Zheng; 2005 Jul; 24(7):827-33. PubMed ID: 16004809
[TBL] [Abstract][Full Text] [Related]
19. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
20. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
